Q-omics provides the consensus-scored MICB profile across patient tissues and cancer cell-line models. MICB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MICB is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MICB RNA expression shows 18,235 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LGG, HNSC, and DLBC as cancer lineages where MICB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MICB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MICB survival associations across molecular data types. MICB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MICB RNA expression–survival associations across cancer types. High MICB expression shows unfavorable associations in LGG, LIHC, MESO and ACC, but favorable associations in BRCA and SCLC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MICB RNA expression.
This table summarizes MICB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MICB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MICB shows higher tumor expression in HNSC, KIRC, BLCA, COAD, STAD and LIHC. The HNSC box plot shows higher MICB RNA expression in tumor versus normal tissue (log2 FC = +1.817, t-test p < 0.001).
This table shows molecular features associated with MICB in patient tissues and cancer cell lines. In patient samples, MICB shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, MICB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
